FSSAI files three cases against Nestlé India over infant formula claims
FSSAI has initiated three adjudication cases involving promotional claims for NAN and Lactogen formulas and an alleged biotin deficiency in a follow-up formula. Nestlé India said its products and labels comply with applicable regulations.
What happened
FSSAI filed three cases against Nestlé India over allegedly non-compliant promotional claims for NAN and Lactogen infant formulas and a follow-up formula’s
Key facts
- 3 separate adjudication cases
- Nestlé India shares fell about 1.4% to ₹1,353.10
- Infant nutrition market valued at $9.92 billion in 2025
- Market projected to reach $13.89 billion by 2031
- Infant milk formula represents nearly 45% of the market
What changed
FSSAI filed three cases against Nestlé India over allegedly non-compliant promotional claims for NAN and Lactogen infant formulas and a follow-up formula’s biotin deficiency. Nestlé said its products and labels comply with applicable regulations.
Why this matters
Nestlé India faces heightened compliance and reputational pressure as FSSAI pursues three cases over infant-formula claims and an alleged nutrient deficiency, despite the company’s assertion that its labels meet regulations.
What to watch
- FSSAI adjudication orders, penalty amounts, mandated label corrections, or directions affecting sale or promotion.
- Whether the biotin allegation is confirmed, limited to a batch, or dismissed after testing and documentation review.
- Any expansion from three cases into additional Nestlé products, manufacturing sites, distributors, e-commerce listings, or industry peers.
- Changes to NAN and Lactogen packaging, online descriptions, advertising copy, or availability.
- Retailer delistings, pharmacy advisories, elevated consumer complaints, or detectable market-share movement in infant formula.
Also reported by
- Mint — Same time